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ABSTRACT
Tumor-initiating cells are responsible for tumor mainte-
nance and relapse in solid and hematologic cancers.
Although tumor-initiating cells were initially believed to be
mainly quiescent, rapidly proliferating tumorigenic cells
were found in breast cancer. In colon cancer, the prolifera-
tive activity of the tumorigenic population has not been
defined, although it represents an essential parameter for the
development of more effective therapeutic strategies. Here,
we show that tumorigenic colon cancer cells can be found in
a rapidly proliferating state in vitro and in vivo, both in
human tumors and mouse xenografts. Inhibitors of polo-like
kinase1 (Plk1), a mitotic kinase essential for cell prolifera-
tion, demonstrated maximal efficiency over other targeted
compounds and chemotherapeutic agents in inducing death
of colon cancer-initiating cells in vitro. In vivo, Plk1 inhibi-
tors killed CD1331 colon cancer cells leading to complete
growth arrest of colon cancer stem cell-derived xenografts,
whereas chemotherapeutic agents only slowed tumor pro-
gression. While chemotherapy treatment increased CD1331
cell proliferation, treatment with Plk1 inhibitors eliminated
all proliferating tumor-initiating cells. Quiescent CD1331
cells that survived the treatment with Plk1 inhibitors could
be killed by subsequent Plk1 inhibition when they exited
from quiescence. Altogether, these results provide a new
insight into the proliferative status of colon tumor-initiating
cells both in basal conditions and in response to therapy and
indicate Plk1 inhibitors as potentially useful in the treatment
of colorectal cancer. STEM CELLS 2012;30:1819–1830
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
Every year more than 1 million people worldwide develop
colorectal cancer, with a mortality of approximately 33% in
developed countries [1]. In the past 5 years, the use of tar-
geted agents has brought an improvement of survival out-
comes for selected categories of colorectal cancer patients.
However, a large portion of patients will not benefit by treat-
ment with monoclonal antibodies and relies on 5-fluoropyri-
midine-based chemotherapeutic regimens. The discovery of
cancer stem cells (CSC) in solid tumors drew a different per-
spective on antineoplastic therapies, following the demonstra-
tion that CSC are extremely resistant to cytotoxic stimuli in
vitro and in vivo as a result of hyperactive DNA repair path-
ways, drug efflux mechanisms, or decreased production of re-
active oxygen species [2–4]. Colon CSC were characterized
on the basis of CD133, Lgr5, or aldehyde dehydrogenase 1
(ALDH 1) expression [5] and were subsequently shown to be
particularly resistant to chemotherapeutic agents [6], possibly
explaining the inability of chemotherapy to eradicate colo-
rectal tumors. Therefore, it is of primary importance to iden-
tify pathways active in CSC that could represent the target for
new antitumor therapies.
CSC proliferation status is highly relevant for cancer ther-
apy. However, while the proliferative activity of stem cells in
normal adult tissues and hematologic cancers has been thor-
oughly investigated, the proliferation of CSC from solid
tumors has only recently started to be explored. Mammary
CSC have been shown to possess an increased replicative
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potential as compared to their normal counterparts and to
undergo more frequent self-renewing divisions [7]. In breast
cancer, these properties are likely responsible for the continu-
ous expansion of the CSC pool, while the ability of CSC to
divide asymmetrically accounts for the production of more
differentiated tumor cells. Normal colon stem cells have been
shown to be actively cycling [8] and to stop dividing when
they differentiate, but the proliferative status of their tumor
counterpart has never been investigated in detail.
Polo-like kinase1 (Plk1) is a serine-threonine kinase that was
originally identified in Drosophila as an essential mitotic regula-
tor [9]. The expression of Plk1 is low in most adult tissues except
for those with a high proliferative index. Conversely, a broad
spectrum of human tumors overexpress Plk1, supporting the
theory that an elevated expression of PLK1 is a general feature
of human cancer [10]. Plk1 inhibition is considered a promising
therapeutic approach in anticancer treatment, and a first wave of
phase I studies aimed at identifying the maximum-tolerated dose
has been recently completed. The Plk1 inhibitor volasertib (BI
6727) has moved to phase II in order to determine its antitumor
activity and safety profile. Preliminary results from a clinical trial
with volasertib as single-agent showed encouraging antitumor ac-
tivity, with nonhematologic adverse events that were mild and
uncommon [11]. We show that colon cancer-initiating cells
(CCIC) are actively proliferating both in vitro and in vivo, over-
express Plk1, and are sensitive to Plk1 inhibitors. Importantly,
Plk1 inhibitors showed enhanced antitumor activity on CCIC-
derived xenografts as compared to chemotherapy, pointing to
Plk1 as a potential therapeutic target in colorectal cancer.
MATERIALS AND METHODS
Cells
Colon cancer specimens were obtained from patients undergoing
surgical resection upon informed consent and approval by the Insti-
tutional Ethical Committee, and subsequent studies were con-
ducted according to the Helsinki Declaration guidelines. CCIC
were selected as previously described (6) and cultured as multicel-
lular spheroids composed of CD133þ cells in serum-free medium
containing epidermal growth factor 20 ng/ml and basic fibroblast
growth factor 10 ng/ml (PeproTech, London, U.K., http://www.
peprotech.com). CCIC differentiation was obtained by culture in
keratinocyte serum-free medium (KSFM) medium or in 10% se-
rum-containing Dulbecco’s modified Eagle’s medium (both from
Gibco-Invitrogen, Carlsbad, CA, http://www.invitrogen.com) for
10 days and confirmed by a decrease in CD133 and Lgr5 expres-
sion. Freshly isolated colon cancer cells were isolated from human
tumor specimens or from CCIC-derived xenografts by magnetic
cell separation with CD133/1 antibody-conjugated microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany, http://www.milte-
nyibiotec.com). To obtain the human CD133 fraction, xenograft-
derived CD133 cells were additionally sorted with an anti-human
epithelial cell adhesion molecule (EpCAM) antibody.
Antibodies and Reagents
BI 2536 was purchased from Axon Medchem (Groningen, The
Netherlands, http://www.axonmedchem.com). Terminal deoxynu-
cleotidyl transferase dUTP nick end labeling (TUNEL) was from
Roche Molecular Biochemicals (Indianapolis, IN, http://www.
roche.com). CD133/1-phycoerythrin (PE) (used for flow cytome-
try/sorting) and CD133/2 (used for immunofluorescence) were
from Miltenyi Biotec. Alexa Fluor-conjugated secondary antibod-
ies were from Invitrogen-Molecular Probes (Eugene, OR, http://
www.invitrogen. com). Anti-PLK1, Ki67, p-ATM, and anti-cyclin
B1 antibodies were from Santa Cruz (Santa Cruz, CA, http://
www.scbt.com). Caspase 3 and 9 antibodies were from Millipore-
Upstate Biotechnology (Billerica, MA, http://www.millipore.-
com). Monoclonal anti-a-tubulin was from Sigma Aldrich (St
Louis, MO, http://www.sigmaaldrich.com). Aurora aurora/IPL1-
related kinase (A/AIK) and anti-phospho-histone H3 (Ser10) were
from Cell Signaling Technology (Beverly, MA, http://www.cell-
signal.com). Secondary anti-mouse and anti-rabbit antibodies
coupled to horseradish peroxidase (HRP) were from GE Health-
care (Uppsala, Sweden, http://www.gehealthcare.com). M30 anti-
body was from Peviva AB (Bromma, Sweden, http://www.pevi-
va.com), and Lgr5 antibody was from Abgent (San Diego, CA,
http://www.abgent.com).> The ALDEFLUOR assay was from
Aldagen, (Durham, NC, http://www.aldagen.com). The APC bro-
modeoxyuridine (BrDU) Flow Kit was from BD Biosciences (San
Diego, CA, http://www.bdbiosciences.com).
PKH Staining
CCIC spheroids were dissociated with TrypLE Express (Invitro-
gen) and stained for 2 minutes at 37C with 1:500 PKH-26 dye
(Sigma-Aldrich, St. Louis, http://www.sigmaaldrich.com), then
washed extensively with PBS, and cultured for 10 days. Cells were
then sorted with a fluorescence-activated cell sorting (FACS) Aria
(Becton Dickinson, Franklin Lakes, NJ, http://www.bd.com) into
PKH-low/negative, -intermediate, and -high fractions. Control cells
did not undergo PKH-26 staining but were mock-sorted to induce
similar stress conditions as in the other sorted samples.
Plk1 RNA Interference
A total of 1.25  105 CCSC were plated on six-well plates in an-
tibiotic-free culture medium and incubated for 4 hours at 37C in
the presence of 320 nM ON-TARGETplus SMARTpool short-
interfering RNA (siRNA) (J-003290-00-0005, Human PLK1,
NM_005030) or control siRNA (nontargeting siRNA D-001810-
01) (Thermo Scientific, Lafayette CO, http://www.thermoscienti-
fic.com) and 5 ll Lipofectamine 2000 (Invitrogen). After 4 hours,
the transfection mixture was substituted with normal growth me-
dium, and cells were analyzed for Plk1 expression, viability, and
morphology at the indicated times.
Library Screening
CCIC spheroids were dissociated with TrypLE Express and 3,000
cells per well were seeded in 96-well microtiter plated at day 0.
On day 2, cells were treated with a library of kinase inhibitors
(Enzo Life Sciences, New York, NY, http://www.enzolifesciences.-
com) used at a 100 nM concentration. In addition, the following
compounds were used at a concentration of 100 nM: BI 2536, Met
kinase inhibitor (PHA-665752), and Aurora kinase inhibitor (PHA-
680632) (both from Selleck Chemicals, Houston, TX, http://
www.selleckchem.com). 5-Fluorouracil (5-FU) and Oxaliplatin
(OXA) (Sigma-Aldrich) were added at a final concentration of 10
lM, which approximates peak plasma values in treated patients.
Cells were processed after 48 hours with the CellTiter-Glo viability
assay (Promega, Madison, WI, http://www.promega.com) accord-
ing to manufacturer’s instructions, and the luminescent signal was
read on a DTX880 microplate reader (Beckman Coulter, Brea, CA,
http://www.beckmancoulter.com). Viability was calculated as fol-
lows: Vs/Mc  100, where Vs represents the integrated intensity
of luminescence counts from the treated sample and Mc represents
the average of the integrated intensities of luminescence counts
from the dimethyl sulfoxide (DMSO) control.
Cell cycle, Apoptosis, and Clonogenicity Assays
The cell cycle status of CCSC was assessed by staining dissoci-
ated spheroids with 50 lg/ml propidium iodide dissolved in
buffer 0.1% trisodium citrate, 9.65 mM NaCl, 0.1% Nonidet P40,
and 200 lg/ml RNase for 1 hour at room temperature. Samples
were analyzed with a FACSCanto flow cytometer (Becton Dick-
inson) equipped with a DIVA software. The CellTiter-Glo assay
(Promega) was used to determine cell viability. A total of 2 
103 dissociated cells were plated at day 0 in 96-well flat bottom
plates. 100 nM BI 2536, 200 mg/ml His-Flag TRAIL, or 40 lM
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zVAD (Bachem, Bubendorf, Switzerland) were added at day 1,
and cells were processed at day 3 according to the manufacturer’s
instructions. Luminescent signal was read using DTX880. Clono-
genicity assay of CCSC was performed by plating 500 single
cells per well in triplicate suspended in 0.3% agarose with or
without BI 2536 over a layer of 0.4% agarose. Plates were incu-
bated in a 5% CO2 humidified incubator at 37
C, and colony
counts were performed 20–25 days after plating. The colonies
were stained with crystal violet (0.1% in 10% MetOH) and
counted under a light microscope. Data shown represent the per-
centage of colony numbers relative to plated cells.
Mice Treatment
Animal experiments were conducted according to the national Ani-
mal Experimentation guidelines (D.L.116/92) upon approval of the
experimental protocol by the Institutional Animal Experimentation
Committee. 6–8-week-old female non-obese diabetic (NOD). Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (The Jackson Laboratory, Bar
Harbor, ME, http://www.jax.org) were subcutaneously injected with
the following number of cells resuspended in 100 ll Matrigel/CCIC
medium 1:1. For BI 6727 or chemotherapy treatment, we used 2.5
 105 cells; for the PKH experiment of Figure 1, we used 2.5 
103 cells; for PKH limiting dilution experiments, we used cell num-
bers indicated in Supporting Information Table 1. Pharmacological
treatments with BI 6727 or chemotherapeutic agents were started
when tumor xenografts reached an approximate volume of 100
mm3. The BI 6727 group (n ¼ 6) was treated by injecting endove-
nously the compound for 2 consecutive days each week (60 mg/kg
weekly) dissolved in 1 N HCl 0.9% NaCl. The chemotherapy group
(n ¼ 6) was treated by injecting intraperitoneally the compounds
(OXA 10 mg/kg, 5-FU 25 mg/kg) resuspended in phosphate buffer
saline (PBS) once a week. The vehicle group (n ¼ 6) was treated
by injecting endovenously 100 ll 1 N HCl 0.9% NaCl twice a
week. Tumor volume was evaluated by using an external digital
caliper, and mice weight was evaluated at the indicated times. Mice
were sacrificed 3 weeks after the beginning of the treatment, and
tumors were removed, weighted, and either embedded in optimal
cutting temperature compound (OCT) and frozen at 80C or proc-
essed for subsequent flow cytometry/sorting. For short-term treat-
ments, the BI 6727 group (n ¼ 6) was injected endovenously with
the compound (40 mg/kg) dissolved as described above, while the
vehicle group (n ¼ 6) was injected with 1 N HCl 0.9% NaCl. After
24 or 48 hours, mice were sacrificed and tumors were removed,
embedded in OCT, and frozen at 80C.
Immunofluorescence
CCIC spheroids were cytospun at low speed on polylysine-coated
glass slides, whereas differentiated colon cancer cells were grown on
Matrigel-coated coverslips. Typically, cells were fixed in 4% parafor-
maldehyde and permeabilized in 0.1% Triton X-100 (Bio-Rad Labo-
ratories, Richmond, CA, http://www.bio-rad.com) then incubated
overnight at 4C with primary antibodies dissolved in PBS containing
3% bovine serum albumin (BSA), 0.1% Triton X-100. After two
washes in PBS, cells were incubated with Alexa Fluor-conjugated
secondary antibodies for 30 minutes at room temperature in the dark,
stained for 15 minutes with 40,6-diamidino-2-phenylindole (DAPI)
(Invitrogen), diluited in PBS 3% BSA, and mounted with Prolong-
Gold antifade (Invitrogen). For actin staining, cells were incubated
for 30 minutes at room temperature with Alexa Fluor 488 phalloidin
1 lM (Invitrogen). For mitochondrial staining, live cells were incu-
bated for 30 minutes at 37C with 100 nM Mitotracker CMXRos
(Invitrogen) then processed for staining with cytochrome c antibody
as described above. Slides were analyzed on a FV1000 confocal
microscope (Olympus, Tokyo, Japan, http://www.olympus-global.-
com) equipped with 60 and 40 oil immersion objectives.
Flow Cytometry and Sorting
Mitochondrial membrane depolarization was measured by flow
cytometry following incubation of dissociated cells with 10 lg/ml
tetramethyl rhodamine methyl ester (Invitrogen Molecular Probes)
for 30 minutes at 37C. For isolation of cells from xenograft tissue,
cells were labeled with EpCAM-fluorescein isothiocyanate (FITC)
(Dako, Glostrup, Denmark, http://www.dako.com) and CD133/1 PE
(Miltenyi Biotec) for 30 minutes at room temperature and sorted
with a FACS Aria (Becton Dickinson). 10 lg/ml 7-aminoactinomy-
cin D (Sigma-Aldrich) was always added for dead cell exclusion.
Western Blotting
Cell lysates were obtained from approximately 2.5  105 colon
cancer initiating cells (CCIC) by incubation of cell pellets in 1%
Nonidet P40 lysis buffer (20 mM Tris-HCl pH 7.2, 200 mM
NaCl, 1% Nonidet P40) supplemented with protease inhibitor
cocktail and phosphatase inhibitor cocktails I and II (all from
Sigma-Aldrich). Lysate concentrations were determined by the
Bradford assay (Bio-Rad Laboratories, Hercules, CA), and equal
amounts of proteins were loaded on a 4%–12% precast gel (Invi-
trogen) and transferred to nitrocellulose membranes. Blots were
blocked with tris-buffered saline Tween-20 (TBST) 5% nonfat
dry milk and incubated overnight at 4C with primary antibodies,
then incubated for 45 minutes with secondary HRP-conjugated
antibodies dissolved in TBST 1% BSA. Chemiluminescent sig-
nals were detected with Super SignalWest Pico (Pierce, Rockford,
IL, http://www.piercenet.com).
Immunohistochemistry
Tumor sections (5–8 lm) were obtained using a cryomicrotome
(Kriostat 1720 MGW Leitz, Melville, NY, http://www.leitz.com).
For CK18 staining, frozen sections were fixed in ice-cold metha-
nol for 4 minutes, endogenous peroxidase activities were blocked
using 0.03% hydrogen peroxide for 15 minutes in the dark, and
then the sections were incubated at room temperature for 1 hour
with M30 antibody. Sections were then processed using avidin-bi-
otin-peroxidase complex (ULTRATEK HRP SCY, Tek Laborato-
ries, West Logan, UT, http://teklabs.com), counterstained with he-
matoxylin, and mounted with DPX (Sigma-Aldrich). For
immunofluorescence analysis, frozen sections were fixed in 4%
paraformaldehyde, permeabilized in 0.1% Triton X-100, and
blocked with 5% serum in PBS containing 1% BSA and 0.1%
Triton X-100. Sections were stained overnight at 4C with pri-
mary antibodies, incubated with fluorochrome-conjugated second-
ary antibodies with 5 mg/ml RNase A, and counterstained with
DAPI. TUNEL staining was performed with the In Situ Cell
Death Detection Kit (Roche Molecular Biochemicals) according
to the manufacturer’s instructions. Azan-Mallory staining was
performed on xenograft cryosections with the Mallory Tricromica
kit (Bio-Optica, Milan, Italy, http://www.bio-optica.it) according
to the manufacturer’s instructions.
Figure 1. All the proliferative subsets of CD133þ cells generate
tumors in mice. CD133þ cells derived from a colon tumor specimen
were cultured as multicellular spheroids (DN08 colon cancer-initiating
cell [CCIC] line), stained with the PKH-26 dye and, after 10 days,
separated into three fractions according to PKH-26 retention. Sorted
cells were inoculated subcutaneously into NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ mice (eight per group). The percentage of tumors that
arose from the different fractions (tumor incidence) is shown above.
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Statistical Analysis
Unless otherwise specified, statistical analysis was conducted by
using two-way ANOVA, and differences between groups/pairs
were evaluated with Bonferroni post tests. Analysis of Figure 6E
was performed with two-tailed unpaired t test. Statistical analysis
was performed with GraphPad Prism v.4.0 for Windows (Graph-
Pad Software, San Diego, CA, www.graphpad.com), and statisti-
cal significance was accepted up to .05. p values are displayed
using a single asterisk for significances ranging from .05 to .01,
two asterisks for values between .001 and .01, and three when
statistical differences produced significance below .001.
RESULTS
Tumorigenic Colon Cancer Cells Are Present in All
Proliferative Subsets of CD1331 Cells
CD133þ colon cancer cells have been previously shown to be
enriched for cells with tumorigenic ability [12, 13]. To inves-
tigate the proliferative state of CCIC, we separated different
subsets of CD133þ CCIC according to their proliferative ac-
tivity and then tested their ability to generate tumors in
immunocompromised mice. To do so, CD133þ cells derived
from surgical specimens were cultured as multicellular sphe-
roids and stained with the fluorescent dye PKH-26, which
binds cell membranes and segregates in daughter cells after
each cell division, thus providing a signal that correlates with
the cell’s proliferation history. After 10 days of PKH staining,
CCIC were FACS-separated into three subsets, PKHLOW/NEG
(very rapidly proliferating), PKHMED (rapidly proliferating),
and PKHHIGH (slowly proliferating). Sorted cells were imme-
diately inoculated in NSG mice (2.5  103 cells each), and
subcutaneous tumor formation was observed after approxi-
mately 2 months. Cells belonging to the PKHMED and
PKHHIGH fractions gave rise to tumors in 100% of mice, as
did bulk control cells from unstained cultures (Fig. 1). Sur-
prisingly, however, also cells of the PKHLOW/NEG subset gave
rise to tumors, although with lower efficiency as compared
with the two other subsets (Fig. 1). These results were sub-
stantiated by limiting dilution experiments showing, in three
different CCIC samples, the presence of tumorigenic cells in
variable amounts in the PKHLOW/NEG fraction (Supporting
Information Table 1). Results from in vitro colony forming
assays confirmed these observations, showing that all three
PKH cell subsets were endowed with colony-forming effi-
ciency (data not shown). PKH distribution was also investi-
gated in cultured CCIC in relation to ALDH activity, which
was previously indicated as a colon stem cell marker [14].
The starting cell population, composed of 100% CD133þ
cells, was separated in PKHLOW/NEG, PKHMED, and PKHHIGH
10 days after PKH staining, and ALDH activity was measured
in the three fractions with the ALDEFLUOR kit. ALDHþ
cells were comparably distributed among the different PKH
fractions, again suggesting an equivalent content of tumori-
genic cells (Supporting Information Fig. S1). These observa-
tions indicate that colon tumor-initiating cells are found both
in slow and fast proliferative states, and they can undergo
rapid cell division without losing their tumorigenic potential.
CCIC Express High Levels of Plk1 and Are Highly
Sensitive to Plk1 Inhibition
Proliferating cells express high levels of the mitotic kinase
Plk1. To determine whether high Plk1 levels were associated
with the CCIC compartment, we investigated Plk1 expression
in colon cancer cells freshly isolated from surgical specimens
or from tumor xenografts. CD133þ tumor cells isolated either
from human tumors or from CCIC-derived mouse xenografts
expressed higher levels of Plk1 as compared with CD133
cells (Fig. 2A), thus suggesting that a highly proliferating
state may be typical of the colon CSC population in vivo.
The correlation between ‘‘stemness’’ and Plk1 expression was
confirmed by comparing seven patient-derived spheroid cul-
tures (described in Supporting Information Table 2) with their
differentiated progeny, composed of adherent cells that have
lost CD133 and Lgr5 expression (Supporting Information Fig.
S2). As expected, Plk1 was more expressed in the stem cell
fraction (Fig. 2B) and was mainly localized on centrosomes of
dividing cells (Supporting Information Fig. S3A). The higher
Plk1 expression in CD133þ CCIC observed in vitro and in
vivo parallels the elevated proliferative activity of CD133þ
cells. In fact, we observed that in vitro CCIC proliferate more
than their differentiated counterparts (Supporting Information
Fig. S4A, S4B), and that in CCIC-derived tumor xenografts,
CD133 expression was mainly associated with Ki67 staining
(Supporting Information Fig. S4C). Due to the high expression
of Plk1 in the CCIC compartment, we ought to investigate the
effect of the Plk1 inhibitor BI 2536 on CCIC in comparison to
a panel of 80 targeted agents and to chemotherapeutic agents
used for colon cancer treatment (5-FU and OXA). Only the
Plk1 inhibitor BI 2536 resulted in a >50% reduction of CCIC
viability after 48 hours in two CCIC lines tested (Fig. 2C; Sup-
porting Information Fig. S3B; compounds’ names are shown in
greater detail in Supporting Information Table 3). A dose-
response assessment of BI 2536 efficacy revealed that CCIC
death was induced already at a 25 nM concentration (Support-
ing Information Fig. S3C). However, we chose a working con-
centration of 100 nM, as this dose was previously shown to
maximally and specifically inhibit Plk1 [15]. To investigate the
in vitro sensitivity to Plk1 inhibitors of differently proliferating
CCIC subsets separated according to PKH staining, we eval-
uated the colony-forming capacity of PKHLOW/NEG, PKHMED,
and PKHHIGH fractions in the presence of BI 2536. None of
the three CCIC subsets was able to generate colonies in semi-
solid culture in the presence of BI 2536 (Fig. 2D), prompting
us to use bulk CCIC cultures for subsequent experiments. The
effect of BI 2536 was then tested on seven patient-derived
CCIC lines, where it was able to inhibit colony formation in 6/
7 cases (Fig. 2E). Importantly, BI 2536 was more effective
than chemotherapeutic agents in reducing CCIC viability in six
of seven CCIC lines tested (Fig. 2F). Finally, we compared the
effect of BI 2536 on stem and differentiated colon cancer cells.
As expected, CCIC resulted more sensitive than their differenti-
ated progeny to Plk1 inhibition (Fig. 2G), according to their
higher proliferative activity.
Plk1 Depletion Recapitulates the Effects of BI 2536
on Colon CSCs
Although highly specific for Plk1, BI 2536 can affect the activ-
ity of other Plks kinases such as Plk2 and Plk3 [15]. To confirm
that the effects observed on CCIC were due to Plk1 inhibition,
we specifically knocked down Plk1 expression by treating two
CCIC lines with targeted short hairpin RNA (shRNA) sequen-
ces. Plk1 protein expression was effectively decreased in RNA
interference (RNAi)-treated cells, as shown by immunoblot
analysis of the two CCIC lines (Fig. 3A). After 48 hours of
RNAi, CCIC with decreased Plk1 expression were characterized
by spheroid disaggregation and by the appearance of cells with
aberrant mitotic spindles (Fig. 3B). The viability of CCIC
treated with Plk1 RNAi, but not with control oligonucleotides,
massively decreased 72 hours after transfection (Fig. 3C), indi-
cating that Plk1 is essential for CCIC survival and that its
downregulation initiates cell death.
Plk1 Inhibition Subverts Cell Cycle
Kinetics in CCIC
To investigate the consequences of Plk1 inhibition in CCIC,
we treated spheroids with BI 2536 for 24 hours and observed
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the appearance of mitotic nuclei in 20%–80% of cells (Fig.
4A, left) which, upon actin/tubulin staining, showed a disor-
ganized cytoskeleton and mitotic spindles typical of the
‘‘Polo’’ phenotype (Fig. 4A, right) [16]. Propidium iodide
staining of BI 2536-treated CCIC showed an accumulation of
cells in the G2/M phase of the cell cycle (Fig. 4B). An evalu-
ation of mitosis-associated proteins showed that BI 2536 treat-
ment resulted in dephosphorylation/activation of Cdc2 and in
cyclin B1 accumulation typical of prophase entry, as con-
firmed by massive histone H3 phosphorylation (Fig. 4C). At
the same time, the Plk1 substrate Cdc25 was progressively de-
phosphorylated (Fig. 4C). In line with previous studies [15],
we found cyclin B1 accumulation in the nucleus of BI 2536-
treated cells, which was maximal at 8 hours (Fig. 4D). These
Figure 2. CCIC overexpress Plk1 and are specifically sensitive to Plk1 inhibitors. (A): Plk1 expression in CD133þ and CD133 cells freshly
isolated from three different colon adenocarcinoma samples (tumor) or from mouse xenografts derived from three different CCIC lines (xeno-
graft). (B): Plk1 expression in CCIC (Stem) and in their differentiated counterparts (Diff). (C): Screening of kinase inhibitor library and chemo-
therapeutic agents on one CCIC line (CCIC 1.1). Cells were treated for 48 hours with the indicated compounds (shown in greater detail in
Supporting Information Table 3), and cell viability was measured as described in Materials and Methods. The arrow indicates the BI 2536-treated
sample. (D): Top: Colonies grown in soft-agar from PKHLOW/NEG, PKHMED, and PKHHIGH fractions separated from one CCIC line (CCIC
DN08), stained as in Figure 1 and plated in the presence (BI 2536) or in the absence () of 100 nM BI 2536. Bottom: Representative picture of
the plates. (E): Top: Colonies generated in soft-agar by seven CCIC lines in the presence (BI 2536) or in the absence () of 100 nM BI 2536.
Bottom: Representative picture of the plates. (F): Cell death induced by 100 nM BI 2536 (BI 2536) or chemotherapeutic agents OXA or 5-FU
(10 lM each) in CCIC lines after 48 hours of treatment. (G): Cell death induced by 48 hours of treatment with BI 2536 in seven lines of CCIC
(Stem) as compared with their differentiated progeny (Diff). ANOVA comparison of stem versus differentiated cells resulted in p < .001. Data
shown in (D–G) are the mean 6 SD of four independent experiments. **, p < .01; ***, p < .001. Abbreviations: CCIC, colon cancer-initiating
cells; OXA, oxaliplatin; Plk1, Polo-like kinase1; 5-FU, 5-fluorouracil.
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observations confirm that Plk1 is dispensable for Cdc2 activa-
tion and cyclin B1 nuclear translocation at mitotic entry [17],
whereas it is essential for Cdc25 phosphorylation in mitotic
cells. Aurora A expression was also investigated upon treat-
ment with BI 2536, as Aurora A plays an important role in
CCIC and is tightly linked to Plk1 in the control of mitotic
progression [18–20]. In untreated CCIC, intense Aurora A
expression was detectable only in dividing cells, whereas the
majority of BI 2536-treated cells expressed high Aurora A
levels (Fig. 4E).
CCIC Respond to Plk1 Inhibitors with DNA
damage, Mitochondrial Depolarization,
and Mitotic Death
Acute Plk1 inhibition has been previously shown to induce ap-
optosis in cancer cell lines [15, 21–24]. Therefore, we analyzed
the effect of BI 2536 in CCIC by assessing signs and mecha-
nisms of cell death. First, we observed ATM phosphorylation/
activation in CCIC after 4 hours of BI 2536 treatment and a
progressive H2AX phosphorylation peaking at 48 hours, indi-
cating the occurrence of a DNA damage response (Fig. 5A,
5B; Supporting Information Fig. S5A). Then, we evaluated typ-
ical hallmarks of apoptosis in treated cells. We found consist-
ent mitochondrial depolarization both in intact spheroids (Fig.
5C) and in dissociated CCIC (Fig. 5D; Supporting Information
Fig. S5B), cytochrome c release from mitochondria (Fig. 5E)
and activation of caspases 3 and 9 (Fig. 5F). However, BI
2536-induced death of CCIC appeared to be mainly caspase-in-
dependent, as the pan-caspase inhibitor carbobenzoxy-valyl-ala-
nyl-aspartyl-[O-methyl]-fluoromethylketone (zVAD-FMK) was
unable to inhibit CCIC death, while it effectively blocked
TNF-related apoptosis-inducing ligand (TRAIL)-induced apo-
ptosis in Jurkat cells (Supporting Information Fig. S5C). In BI
2536-treated CCIC, the majority of cells acquired a giant size
(Supporting Information Fig. S5D) and up to 10% of the cells
became polyploid (Fig. 5G), indicating that CCIC undergo mi-
totic cell death in the presence of Plk1 inhibitors.
Plk1 Inhibition In Vivo Results in CCIC Death
and Tumor Growth Arrest
CSC are characterized by the ability to reproduce the original
human tumor in immunocompromised mice, thus representing
a powerful tool to evaluate the effect of anticancer agents in
vivo. We investigated the effect of Plk1 inhibition on CCIC-
derived tumor xenografts obtained through subcutaneous
injection of CCIC, which reproduced the histological structure
of the parental colorectal tumor (Fig. 6A). For in vivo experi-
ments we used BI 6727, a dihydropteridinone Plk1 inhibitor
similar to BI 2536 with comparable activity toward CCIC in
vitro (data not shown) and an improved pharmacokinetic pro-
file in vivo [25]. Analysis of cell cycle and apoptosis markers
performed on CCIC-derived xenografts upon a short-time
treatment with BI 6727 revealed a widespread induction of
histone H3 phosphorylation at 24 hours (Fig. 6B) indicating
the occurrence of mitotic arrest in the majority of cells. Cas-
pase 3 was massively activated in BI 6727-treated xenografts
at 48 hours of treatment as shown by extensive staining for
cleaved cytokeratin (Supporting Information Fig. S6A).
Importantly, a double staining for CD133 and TUNEL on
xenograft sections revealed that areas of cell death widely
overlapped with stem cell areas identified by CD133 positivity
in BI 6727-treated samples but not in chemotherapy-treated
samples (Fig. 6C), indicating that BI 6727 specifically induces
CCIC apoptosis in vivo. Similar results were obtained by dou-
ble staining of xenografts sections with Lgr5 and TUNEL
(Supporting Information Fig. S6B). A 21-day treatment with
BI 6727 resulted in complete block of tumor growth, whereas
standard chemotherapeutic agents (OXA plus 5-FU) were
Figure 3. RNA interference against Plk1 results in CCIC death. (A): Plk1 expression detected 48 hours after transfection in two CCIC lines (CCIC
1.2 and CRO) transfected with control (CTRL siRNA) or anti-Plk1 (siRNA Plk1) RNA sequences. (B): Actin/tubulin staining performed 48 hours af-
ter transfection of two CCIC lines treated as in (A); white arrows indicate aberrant mitotic spindles. (C): Cell death detected 72 hours after transfec-
tion in two CCIC lines treated as in (A). Data shown are the mean 6 SD of three independent experiments. Abbreviations: CCIC, colon cancer-
initiating cells; DAPI, 40,6-diamidino-2-phenylindole; DIC, differential interference contrast; Plk1, Polo-like kinase1; siRNA, short-interfering RNA.
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only able to slow xenograft expansion (Fig. 6D). Assessment of
tumor size and weight at the end of treatment confirmed that the
growth of CCIC xenografts was strongly inhibited by BI 6727
and at a lesser extent by chemotherapeutic agents (Fig. 6E).
Quiescent CD133 Cells Escape BI 6727 Treatment
but Retain Sensitivity to Subsequent Plk1 Inhibition
To investigate the long-term effects of BI 6727 on xenograft
stem cell populations, we examined xenografts treated for 21
days with either chemotherapeutic agents or BI 6727. Azan-
Mallory staining of xenograft sections revealed that BI 6727-
treated tumors contained large fibrotic areas, whereas chemo-
therapy-treated tumors showed a dense cellular structure (Fig.
7A). A quantitative evaluation of CD133þ cells present in
tumor xenografts revealed that the percentage of CD133þ
cells was increased both in chemotherapy-treated samples and
in BI 6727-treated samples as compared with vehicle-treated
controls (Fig. 7B). However, taking into account xenograft
volume at the end of the treatment, the absolute CCIC content
at the end of the treatment proved to be significantly lower in
BI 6727-treated samples as compared to both controls and
chemotherapy-treated samples (Fig. 7C). Moreover, a double
staining for CD133 and Ki67 on xenograft sections revealed
that, in chemotherapy-treated tumors, CD133þ cells were
actively proliferating. Conversely, in BI 6727-treated tumors,
residual CD133þ cells were completely quiescent (Fig. 7D).
These observations indicate that treatment with Plk1 inhibi-
tors, although does not completely eradicate the CD133þ pop-
ulation, eliminates all the proliferating tumorigenic cells. To
understand whether CCIC that survived BI 6727 treatment
developed resistance to Plk1 inhibition, we isolated
EpCAMþ/CD133þ cells from vehicle-treated and BI 6727-
treated xenografts, kept them in culture for 4 weeks, and then
treated them with BI 6727 in comparison with the parental
CCIC line. Sensitivity to BI 6727 was virtually identical in
the three populations (Fig. 7E), indicating that CD133þ cells
that survive treatment with Plk1 inhibitors in vivo do not
Figure 4. Plk1 inhibition by BI 2536 alters cell cycle kinetics in CCIC. (A): Percentage of mitotic nuclei in CCIC lines untreated () or
treated for 24 hours with 100 nM BI 2536 (left) and actin/tubulin immunofluorescence staining of CCIC (AG2) treated for 24 hours with 100 nM
BI 2536 (right). (B): Cell cycle analysis of CCIC treated for 24 hours with 100 nM BI 2536. Data shown are the mean 6 SD of three independ-
ent experiments. (C): Western blot analysis of cyclin B1, p-Cdc2, p-Cdc25, and p-histone H3 (pH3) in the CCIC line AG2 untreated or treated
for the indicated times with 100 nM BI 2536. (D): Immunofluorescence analysis of cyclin B1 localization in the CCIC line AG2, untreated or
treated for the indicated times with 100 nM BI 2536. (E): Immunofluorescence analysis of Aurora A expression in the CCIC line AG2 untreated
() or treated for 24 hours with 100 nM BI 2536 (BI 2536). Abbreviations: CCIC, colon cancer-initiating cells; Cdc, cell division cycle; DAPI,
40,6-diamidino-2-phenylindole; DIC, differential interference contrast; Plk1, Polo-like kinase1.
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acquire resistance to Plk1 inhibitors. Altogether these observa-
tions indicate that, in vivo, CCIC respond to chemotherapeu-
tic agents with increased proliferation, whereas in the pres-
ence of Plk1 inhibitors CCIC are found in a quiescent state
resulting in inhibition of tumor growth.
DISCUSSION
Stem cells of normal adult tissues are predominantly found in
a quiescent state, from which they egress to replenish the
Figure 5. BI 2536 induces DNA damage and mitotic death of CCIC (line AG2). (A): ATM phosphorylation in CCIC, untreated () or treated
for 4 hours with100 nM BI 2536. (B): Histone H2AX phosphorylation in CCIC untreated () or treated for 24 hours with 100 nM BI 2536. (C):
Mitochondrial depolarization in live intact spheroids (JC-1 staining) treated for the indicated times with 100 nM BI 2536. 60 magnification, 2
zoom. (D): Mitochondrial depolarization in dissociated CCIC (TMRM staining) treated for the indicated times with 100 nM BI 2536. Data shown
are the mean 6 SD of three datasets obtained in independent experiments. (E): Cytochrome c release from mitochondria in CCIC untreated ()
or treated for 24 hours with 100 nM BI 2536 (BI 2536); 60 magnification, 2 zoom. (F): Activation of caspases 3 and 9 in CCIC treated for
the indicated times with 100 nM BI 2536. (G): Actin/tubulin staining in untreated CCIC () compared with a giant polyploid CCIC obtained by
treatment for 72 hours with 100 nM BI 2536 (60 magnification, 3 zoom). Abbreviations: ATM, ataxia-telangiectasia mutated; CCIC, colon
cancer-initiating cells; DAPI, 40,6-diamidino-2-phenylindole; DIC, differential interference contrast; Plk1, Polo-like kinase1; JC-1, 5,50,6,60-tetra-
chloro-1,10,3,30-tetraethylbenzimidazolyl carbocyanine iodide; TMRM, tetramethylrhodamine methyl ester.
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Figure 6. Plk1 inhibitors target CCIC in vivo and block the growth of CCIC-derived xenografts. (A): Hematoxylin/Eosin staining of a CCIC-
derived xenograft section (lower panel, cryosection) and of the parental patient tumor (upper panel, paraffin-embedded), 10 magnification. (B): Phos-
pho-histone H3 (pH3) staining of xenograft sections obtained from mice treated for 24 hours with vehicle () or with BI 6727 (BI 6727), 60 magni-
fication. (C): Immunofluorescence staining (40 magnification) for CD133 and TUNEL of xenograft sections derived from mice treated for 48 hours
with vehicle () or with BI 6727 (BI 6727). (D): Tumor volume of xenografts treated with vehicle only (vehicle), with chemotherapeutic agents
(OXAþ5-FU) and with BI 6727 (BI 6727) as described in Materials and Methods section. Statistical analysis is shown in the table beneath, where ns
stands for ‘‘nonsignificant’’. Two-way ANOVA resulted in p < .001. The results shown are representative of four independent experiments. (E): Tu-
mor weight at the end of treatment and representative picture. Data shown are the mean 6 SD of six samples per group relative to the experiment
shown in (D). *, p < .05; ***, p < .001. All the experiments in this figure were performed with the CCIC line AG2 and replicated on the CCIC line
DN08 with similar results. Abbreviations: CCIC, colon cancer-initiating cells; DAPI, 40,6-diamidino-2-phenylindole; DIC, differential interference con-
trast; OXA, oxaliplatin; Plk1, Polo-like kinase1; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; 5-FU, 5-fluorouracil.
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Figure 7. BI 6727-treated xenografts contain quiescent CD133þ cells that retain sensitivity to Plk1 inhibitors. (A): Azan-Mallory staining of xeno-
graft sections derived from vehicle-treated (vehicle), chemotherapy-treated (OXAþ5-FU), and BI 6727-treated mice after 3 weeks of treatment. 10
magnification. (B): Percentage of CD133þ/EpCAMþ cells present in xenografts after 3 weeks of treatment with vehicle only (vehicle), chemotherapy
(OXAþ5-FU), or BI 6727. Data shown are the mean 6 SD of five samples per group. (C): Total stem cell content in tumor xenografts relative to
the experiment shown in Figure 6B. Values were calculated as tumor weight  percentage of EpcamþCD133þ cells/100. (D): Immunofluorescence
staining (40 magnification) of Ki67 and CD133 in xenograft sections obtained after 3 weeks of treatment with vehicle only (vehicle), chemother-
apy (OXAþ5-FU), or BI 6727. (E): Cell death induced by treatment in vitro with 100 nM BI 6727 for 48 hours of the parental CCIC line and of
EpCAMþ/CD133þ cells extracted from vehicle-treated (xenograft vehicle) or BI 6727-treated (xenograft BI 6727) xenografts after 3 weeks of in
vivo treatment. Data shown are the mean 6 SD of three samples per group. All the experiments in this figure were performed with the CCIC line
AG2. Abbreviations: A.U.: arbitrary units; CCIC, colon cancer-initiating cells; DAPI, 40,6-diamidino-2-phenylindole; DIC, differential interference
contrast; EpCAM, epithelial cell adhesion molecule; OXA, oxaliplatin; Plk1, Polo-like kinase1; 5-FU, 5-fluorouracil.
pool of more differentiated cells. A similar hierarchy of pro-
liferating cells is found in hematologic malignancies, where a
population of quiescent stem cells retains the ability to trans-
fer the disease in experimental animals, likely being responsi-
ble for drug resistance and relapse in leukemia patients. Dif-
ferently from other stem cell types, normal colon stem cells
have been found to be actively proliferating, both in mice and
in humans [26, 27]. Proliferation of CSCs from solid tumors
has been mainly investigated in breast cancer, where tumori-
genic cells have been demonstrated to possess a replicative
activity higher than their normal counterparts [7]. This fea-
ture, together with their predilection toward symmetric divi-
sion, may be responsible for continuous expansion of the
breast CSC population. Characterizing the proliferation state
of CSCs has strong therapeutic implications, as identifying
altered cell division mechanisms present in tumorigenic cells
may indicate effective routes to eradicate this population. We
found that CCIC comprise both rapidly and slowly proliferat-
ing cells. Consistently with a sustained proliferative activity
in vivo, CCIC freshly isolated from colon cancer specimens
express high levels of Plk1, a kinase essential for multiple
steps of cell division. Although not specifically considered as
part of the classic stem cell equipment, increased Plk1 expres-
sion was previously identified as part of a gene signature con-
comitantly altered in both normal stem cells and metastatic
prostate cancer cells [28], suggesting the existence of a link
between stemness and deregulated expression of Plk1. More
generally, high Plk1 activity is considered as a tumor-promot-
ing force, as it has been demonstrated to stimulate mitosis,
override DNA damage checkpoints, support cell invasion, and
facilitate the insurgence of aneuploidy [10].
Plk1 inhibitors have been recently demonstrated to be par-
ticularly cytotoxic for neuroblastoma tumor-initiating cells and
for breast cancer-initiating cells, suggesting that they may rep-
resent an interesting therapeutic option in multiple tumor types
[29, 30]. Our results demonstrate that, in colon tumors, the use
of Plk1 inhibitors resulted in CCIC death both in vitro and in
vivo, showing an increased efficacy over chemotherapeutic
agents. Due to their enhanced antitumor effect as compared
with conventional chemotherapy, Plk1 inhibitors may prove
particularly useful in the preoperative setting, when a rapid
reduction of tumor volume is required in order to perform radi-
cal surgery and/or preserving organ function. For instance,
Plk1 inhibitors may be indicated for the preoperative treatment
of colorectal cancer patients with unresectable liver metastatic
disease. In this case, Plk1 inhibitors (which are not associated
to significant hepatobiliary toxicity) would have a clear advant-
age over chemotherapeutic agents, which cause considerable
liver damage further increasing liver injury due to hepatic me-
tastases and surgical resection. To a similar extent, BI 6727
could be exploited in the neoadjuvant setting for treating rectal
cancer patients; in this setting, there is an urgent need for iden-
tifying therapeutic options safer than standard chemoradiation
protocols as well as to increase the rate of sphincter-preserving
surgery when tumors arise from the distal rectum.
Specific analysis of CCIC proliferation state in xenografts
treated for 3 weeks with chemotherapy or Plk1 inhibitors showed
that chemotherapy-treated tumors, although smaller than control
tumors, contained actively proliferating CD133þ cells. Con-
versely, tumors treated with Plk1 inhibitors had a smaller size
and contained only quiescent CD133þ cells. These observations
indicate that Plk1 inhibitors block tumor growth by eliminating
all the proliferating tumorigenic cells. This situation reminds the
effect of imatinib in chronic myeloid leukemia (CML), where the
breakpoint cluster region-Abelson (BCR-ABL) inhibitor selec-
tively eliminates proliferating leukemia cells [31, 32]. The inabil-
ity of imatinib to eliminate quiescent stem cells, together with
the propensity of neoplastic cells to acquire BCR-ABL kinase
domain mutations results, in most cases, in persistence of the ma-
lignant CML clone. Differently, quiescent CCIC that survive
treatment with Plk1 inhibitors in vivo do not acquire resistance to
these drugs suggests that, in line of principle, they may be tar-
geted by sequential rounds of BI 6727 treatment or by alternate
rounds of chemotherapy/Plk1 inhibitors.
CONCLUSION
Our results indicate for the first time that colon cancer tumori-
genic cells actively proliferate in vivo and are characterized
by an elevated expression of Plk1, which constitutes a rele-
vant therapeutic target. Future studies will be crucial to eluci-
date the mechanisms that control CSC quiescence and prolif-
eration, as influencing this balance may render tumorigenic
cells susceptible to targeted therapeutic strategies.
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